Objective To investigate the pathogens of ventilator-associated pneumonia (VAP) and their drug resistance in the pediatric intensive care unit (PICU) in high-altitude areas and to provide a clinical basis for the prevention and treatment of VAP. Methods A total of 94 children with VAP hospitalized in the PICU in high-altitude areas between June 2011 and June 2013 were recruited. Their lower respiratory tract secretions were collected for bacterial culture and drug sensitivity test. Results Of the 94 children with VAP, 22 (23%) had a single bacterial infection, and 72 (77%) had mixed infections, mostly with Klebsiella pneumoniae and Acinetobacter baumannii (17 cases, 27%). Of the 178 isolated strains of pathogens, 139 (78%) were Gram-negative bacteria (G- bacteria), mainly including Klebsiella pneumoniae, Stenotrophomonas maltophilia, Acinetobacter baumannii, and Pseudomonas aeruginosa, 26 (15%) were Gram-positive bacteria (G+ bacteria), mainly including Staphylococcus aureus, and 13 (7%) were fungi, mainly including Candida albicans. Most G- bacteria had a high drug resistance. Pseudomonas aeruginosa was extensively drug-resistant. Acinetobacter baumannii was only highly sensitive to cefoperazone/sulbactam and imipenem. Multidrug resistance (methicillin resistance) was found in G+ bacteria, for which vancomycin was effective. Conclusions The pathogens of VAP in high-altitude areas are mostly G- bacteria, which may cause mixed infections and develop drug resistance. This provides guidance for the rational use of antimicrobial drugs and the development of key prevention and control measures for VAP.
Key words
High-altitude area /
Intensive care unit /
Ventilator-associated pneumonia /
Pathogen /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 姚庆镛, 卢秀英, 韩锦玲, 等. 高原地区小儿急性呼吸衰竭 的临床研究[J]. 高原医学, 1993, 3(4): 24-26.
[2] 许峰, 罗雁红. 呼吸机相关肺炎的诊断及治疗[J]. 小儿急救 医学, 2002, 9(4): 202.
[3] 肖小六. 呼吸机相关肺炎的研究进展[J]. 临床内科杂志, 2012, 29(3): 209-211.
[4] 虞燕波, 段美丽, 李昂, 等. VAP 诊疗进展[J]. 中国全科医学, 2007, 10(1): 72-74.
[5] Wilke M, Grube RF, Bodmann KF. Guideline adherent initial intravenous antibiotic therapy for hospital-acquired, ventilatorassociated pneumonia is clinically superior, saves lives and is cheaper than non guide line adherent therapy[J]. Eur J Med Res, 2011, 16(7): 315-323.
[6] Lagamayo EN. Antimicrobial resistance in major pathogens of hospital-acquired pneumonia in Asian countries[J]. Am J Infect Control, 2008, 36(4 Supp1): S101-S108.
[7] 葛怡. 重症监护病房呼吸机相关肺炎的病原菌耐药性分析及 防治策略[J]. 临床肺科杂志, 2012, 17(12): 2271-2272.
[8] 邓阳彬, 武海滨, 常文毅. 儿童重症监护室呼吸机相关肺炎 病原学分析[J]. 陕西医学杂志, 2008, 37(1): 53-54.
[9] 王洪斌, 何代平, 蒋红梅, 等. 高原地区医院感染的细菌学 研究[J]. 西南军医, 2005, 7(2): 1-2.
[10] 陈群英, 黄明海. 大肠埃希菌与肺炎克雷伯菌超广谱β 内 酰胺酶的临床分布及药敏分析[J]. 中华医院感染学杂志, 2008, 9(8): 1000-1002.
[11] 周北燕, 卢光进. 环丙沙星治疗新生儿呼吸机相关肺炎的疗 效观察[J]. 中国当代儿科杂志, 2002, 4(5): 407-408.